Lupin’s share price surged by more than 3% early on Wednesday following the announcement of its intention to construct a cutting-edge pharmaceutical manufacturing plant in Coral Springs, Florida. This strategic decision represents a significant expansion of the Indian pharmaceutical company’s presence in the United States, solidifying its position as a key player in the global respiratory sector.
As of 9:28 am, Lupin’s shares were trading at Rs 1,968.75, marking an increase of Rs 63.05, or 3.31%, on the Bombay Stock Exchange (BSE).
The planned Coral Springs facility, as outlined by Lupin, will require an estimated total investment of $250 million over the next five years, encompassing research and development, infrastructure enhancements, and capital expenditures. Once operational, the facility will have the capacity to manufacture more than 25 essential respiratory medications, including crucial albuterol inhalers for children with asthma and for use by US military personnel.
Lupin emphasized that the project will not only bolster its manufacturing capabilities but also enhance the domestic production of vital medicines in the United States, contributing to supply chain diversification and national healthcare security. The company anticipates that the new facility will create over 200 skilled, long-term jobs in Broward County by 2030.
Christoph Funke, Lupin’s Chief Technical Operations Officer, stated, “The expansion of Lupin’s presence in Coral Springs is a key component of our growth strategy. This advanced facility will complement our existing operations in Florida, where our headquarters and Advanced Inhalation Research Center are located.”
Funke highlighted that this investment underscores Lupin’s dedication to innovation, quality, and supply chain resilience, showcasing its ability to collaborate with US partners to ensure affordable access to respiratory treatments.
Investors have responded positively to the announcement, viewing it as a strong indication of Lupin’s commitment to long-term global expansion and its aspiration to capture a greater market share in the US respiratory therapy sector, which has experienced heightened demand post-pandemic.
Moreover, Lupin’s strategic move aligns with Washington’s efforts to enhance domestic pharmaceutical manufacturing and reduce reliance on international suppliers, positioning the company strategically within a critical policy priority area for the US healthcare system.